Figure 4
Figure 4. Proliferation of CD28 and p110δ double mutant T cells. (A) Anti-CD3– and anti-CD28–dependent proliferation of WT, p110δD910A/D910A, CD28−/−, CD28Y170F, p110δD910A/D910ACD28−/−, and p110δD910A/D910ACD28Y170F lymph node T cells stimulated with 0.1 μg/mL anti-CD3 and with anti-CD28 37.51 hybridoma supernatant (1/100). (B) Proliferation of T cells from the mutants OT-II+ transgenic WT, p110δD910A/D910A, CD28−/−, CD28Y170F, p110δD910A/D910ACD28−/−, and p110δD910A/D910ACD28Y170F CD4+ T cells in response to 0.01μM, 0.1μM, or 1.0μM OVA323-339 peptide.

Proliferation of CD28 and p110δ double mutant T cells. (A) Anti-CD3– and anti-CD28–dependent proliferation of WT, p110δD910A/D910A, CD28−/−, CD28Y170F, p110δD910A/D910ACD28−/−, and p110δD910A/D910ACD28Y170F lymph node T cells stimulated with 0.1 μg/mL anti-CD3 and with anti-CD28 37.51 hybridoma supernatant (1/100). (B) Proliferation of T cells from the mutants OT-II+ transgenic WT, p110δD910A/D910A, CD28−/−, CD28Y170F, p110δD910A/D910ACD28−/−, and p110δD910A/D910ACD28Y170F CD4+ T cells in response to 0.01μM, 0.1μM, or 1.0μM OVA323-339 peptide.

or Create an Account

Close Modal
Close Modal